Download Files:

Talazoparib

SKU T6253-1 mL * 10 mM (in DMSO) Category Small Compound Brand: TargetMol

Price range: 56 CAD through 1,173 CAD

For Research Use Only (RUO). This product is sold strictly for laboratory research use. Not for human or veterinary consumption, therapeutic, or diagnostic use.For sale to research organizations and laboratories only; not for patients or for personal use.

Size

2 mg 1 mL * 10 mM (in DMSO)10 mg 100 mg 200 mg 25 mg 5 mg 50 mg 500 mg

Clear

Products Details

Product Description

– Talazoparib (LT-673) is a new-type PARP inhibitor (IC50: 0.58 nM), It similarly binds to PARP1/2 (Kis: 1.2/0.85 nM).

For Research Use Only (RUO). This product is sold strictly for laboratory research use only. Not for human or veterinary consumption, therapeutic, or diagnostic use. Any pharmacological, therapeutic, cosmetic, or biological effects described above are provided as research context only and do not represent intended or approved uses of this product.

Web ID

– T6253

Storage Temperature

– -20℃

Shipping

– Blue Ice

Molecular Formula

– C19H14F2N6O

Citations

– 1. Hou X, Tian M, Ning J, et al.PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause.International Journal of Biological Sciences.2023, 19(12): 3970. 2. Mateos-Pujante A, Jiménez M C, Andreu I.Assessment of the PARP inhibitor talazoparib photosafety profile.Biomedicine & Pharmacotherapy.2023, 167: 115593. 3. Kamaletdinova T, Zong W, Urbánek P, et al.Poly (ADP-Ribose) Polymerase-1 Lacking Enzymatic Activity Is Not Compatible with Mouse Development.Cells.2023, 12(16): 2078. 4. Kiehlmeier S, Rafiee M R, Bakr A, et al. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia. Leukemia. 2021 Nov;35(11):3127-3138. doi: 10.1038/s41375-021-01235-z. Epub 2021 Apr 28. 5. Liu C, Li J, Xu F, et al.PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.Molecular Cancer.2024, 23(1): 111. 6. Liu S, Deng P, Yu Z, et al.CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.Advanced Science.2024: 2403782. 7. Lodovichi S, Nepomuceno T C, Woods N T, et al.SART1 modulates Poly-(ADP-Ribose) chain accumulation and PARP1 chromatin localization.iScience.2024

References

– Wilkerson PM, et al. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. Oncotarget. 2017 Jan 24;8(4):6057-6066.

CAS Number

– 1207456-01-6

Molecular Weight

– C19H14F2N6O

Compound Purity

– 0.9992

SMILES

– Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1

Pathway

– Chromatin/Epigenetic|||DNA Damage/DNA Repair

Product type

– Small Compound

Booklet

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.